BRIEF—Idorsia announces executive promotions

Swiss biotech Idorsia today announced the appointment of Guy Braunstein, who has served as head, global clinical development since the creation of Idorsia and before, since 2009 at Actelion, to a newly created role – chief medical officer (CMO) and affirms that he will continue to serve as a member of the Idorsia executive committee (IEC) in this new position.

Alberto Gimona, who has served as the head of therapeutic area units since February 2019 within global clinical development, will succeed Mr Braunstein as head of global clinical development and join the IEC. Both roles are effective immediately.

The CMO role will ensure that Idorsia’s approach to medical governance and its policies and procedures are globally aligned and consistent across Drug Discovery, Clinical Development, Pharmaceutical Development and Global and Local Medical Affairs.